Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies
Clinical Lymphoma Myeloma and Leukemia · 2023
DOI: 10.1016/j.clml.2023.04.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023. Verfasst von Dilan A Patel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Washington University in St Louis School of Medicine, St Louis, MO, 63110. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
INTRODUCTION: Mantle cell lymphoma (MCL) is a moderately aggressive lymphoma subtype, generally viewed as incurable. For younger, fit patients, the standard of care remains various high-dose cytarabine-based induction regimens followed by autologous hematopoietic cell transplant and 3 years of rituximab maintenance. Despite reasonably good outcomes, with median progression-free survival in the range of 7 to 9 years, most patients eventually relapse, indicating a need to improve the safety and tolerability of remission induction strategies. METHODS: Given the impressive activity of bendamustine/rituximab (BR) in older patients with MCL, we developed an induction regimen modeled after the Nordic Regimen but substituted BR in place of R-CHOP. In a second pilot study, we incorporated the second-generation Bruton tyrosine kinase inhibitor (BTKi), acalabrutinib, into the regimen. The primary endpoint of both studies was stem cell mobilization success rate. RESULTS: All patients successfully underwent stem cell harvest in both studies. CONCLUSION: The experience from our single institution pilot study suggested that sequential rather than alternating BR and cytarabine/rituximab (CR) was easier to administer from the standpoint of toxicities and subsequent dose modifications. Safety and efficacy data from the 2 pilot studies, FitMCL 1.0 and 2.0, were similar. The pilot studies provided preliminary safety data supporting the development of the NCTN trial EA4181, assessing three different induction regimens with or without acalabrutinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Washington University in St Louis School of Medicine, St Louis, MO, 63110.
- Washington University in St Louis School of Medicine, St Louis, MO, 63110. Electronic address: bkahl@wustl.edu.
Förderung
- NCI NIH HHS
Zitieren
APA
Patel, D. A., Wan, F., Trinkaus, K., Guy, D. G., Edwin, N., Watkins, M., Bartlett, N. L., Cashen, A., Fehniger, T. A., Ghobadi, A., Shah, N. M., & Kahl, B. S. (2023). Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.04.003
Vancouver
Patel DA, Wan F, Trinkaus K, Guy DG, Edwin N, Watkins M, et al. Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies. Clinical Lymphoma Myeloma and Leukemia. 2023. doi:10.1016/j.clml.2023.04.003
BibTeX
@article{Patel2023,
author = {Patel, Dilan A and Wan, Fei and Trinkaus, Kathryn and Guy, Daniel G and Edwin, Natasha and Watkins, Marcus and Bartlett, Nancy L and Cashen, Amanda and Fehniger, Todd A and Ghobadi, Armin and Shah, Neha-Mehta and Kahl, Brad S},
title = {Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2023},
doi = {10.1016/j.clml.2023.04.003}
}
EUVIMED